Cullinan Therapeutics Prepares Q2 2026 CLN-978 Data Readout with AML Fast Track
Cullinan Therapeutics will report Phase 1/2 Q2 2026 data for its bispecific T-cell engager CLN-978 targeting CD3 and CD123 in acute myeloid leukemia. The company also holds FDA Fast Track designation for its AML program, positioning CLN-978 for accelerated regulatory review.
1. Catalyst-Heavy 2026 Roadmap
Cullinan has scheduled a mid-2026 release of Phase 1/2 Q2 data for CLN-978, its bispecific T-cell engager directed at CD3 and CD123 for AML, following receipt of FDA Fast Track status to accelerate the clinical and regulatory pathway for its lead oncology asset.
Related News
NVDA
Nvidia Raises Dividend to $0.25, Launches $80B Buyback after $91B Forecast
NVDA•
QQQ
Nasdaq-100 ETF Trackers Eye 30% EM Earnings Growth and Nvidia’s $78.8B Quarter
QQQ•
JPM
J.P. Morgan Joins SpaceX $1.75 Trillion Nasdaq IPO With $1.45B Bitcoin Disclosure
JPM•
GS
Goldman Sachs to Lead $1.75 Trillion SpaceX IPO With $1.45B Bitcoin Disclosure
GS•
INTU
Intuit to Launch AI-Driven Platforms in August, Cuts 17% Workforce to Fund Growth
INTU•
Sources
F